Comparative Pharmacology
Head-to-head clinical analysis: CAP PROFEN versus PREVACID NAPRAPAC 250 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAP PROFEN versus PREVACID NAPRAPAC 250 COPACKAGED.
CAP-PROFEN vs PREVACID NAPRAPAC 250 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAP-PROFEN is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis and resulting in anti-inflammatory, analgesic, and antipyretic effects.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day.
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
None Documented
None Documented
2-4 hours (terminal half-life); prolonged in elderly (up to 6 h) and renal impairment.
Naproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
Primarily renal (70-80% as unchanged drug and glucuronide conjugate), with 10-15% biliary/fecal. Less than 5% unchanged in urine.
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Category C
Category C
Opioid and NSAID Combination
Proton Pump Inhibitor/NSAID Combination